HT1054 | 52059-62-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: HT1054
• 英文别名: 5-(3-methoxyphenyl)-1,3,4-oxathiazol-2-one；5-(3-methoxy-phenyl)-[1,3,4]oxathiazol-2-one；5-(3-Methoxy)phenyl-1,3,4-oxathiazol-2-on
• CAS: 52059-62-8
• 化学式: C₉H₇NO₃S
• 分子量: 209.225
• InChiKey: WJLUBQGCNMULCT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.11
• 拓扑面积：
  73.2
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  N-m-Methoxyphenyltrichlormethansulfenamid 在 三乙胺 作用下， 以 苯 为溶剂， 反应 0.25h， 生成 HT1054
  参考文献：
  名称：

  Koval', I. V.; Oleinik, T. G.; Tarasenko, A. I., Journal of Organic Chemistry USSR (English Translation), 1985, vol. 21, # 12, p. 2358 - 2365

  摘要：

  DOI：

文献信息

• Optimization and Evaluation of 5-Styryl-Oxathiazol-2-one<i>Mycobacterium tuberculosis</i>Proteasome Inhibitors as Potential Antitubercular Agents
  作者：Francesco Russo、Johan Gising、Linda Åkerbladh、Annette K. Roos、Agata Naworyta、Sherry L. Mowbray、Anders Sokolowski、Ian Henderson、Torey Alling、Mai A. Bailey、Megan Files、Tanya Parish、Anders Karlén、Mats Larhed

  DOI：10.1002/open.201500001

  日期：2015.6

  5‐styryl‐oxathiazol‐2‐ones as inhibitors of the Mycobacterium tuberculosis (Mtb) proteasome. As part of the study, the structure–activity relationship of oxathiazolones as Mtb proteasome inhibitors has been investigated. Furthermore, the prepared compounds displayed a good selectivity profile for Mtb compared to the human proteasome. The 5‐styryl‐oxathiazol‐2‐one inhibitors identified showed little activity

  这是5-苯乙烯基草并恶唑-2-酮类药物作为结核分枝杆菌（Mtb）蛋白酶体抑制剂的首次报道。作为研究的一部分，已研究了草硫唑酮作为Mtb蛋白酶体抑制剂的构效关系。此外，与人蛋白酶体相比，制备的化合物对Mtb表现出良好的选择性。鉴定出的5-styryl-oxathiazol-2-one抑制剂对复制Mtb几乎没有活性，但对非复制细菌具有快速杀菌作用。（E）‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 4 ‐‐‐‐‐‐‐‐yré‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ was ‐‐‐‐‐‐‐‐‐‐一was- ‐‐‐‐‐‐‐‐‐‐‐‐ 4？-‐‐‐‐‐‐‐‐‐‐‐‐‐‐5å？-‐‐‐‐‐‐‐‐‐‐‐‐ was？-‐‐‐‐‐‐‐‐‐‐‐‐waså？-‐‐‐ 5-（4-Chlorostyryl）‐1,3,4-Oxathiazol−2-1？的效果最佳，在所有测试浓度下的集落形成单位（CFU）/ mL仅在小于
• Senning,A.; Rasmussen,J.S., Acta Chemica Scandinavica (1947), 1973, vol. 27, # 6, p. 2161 - 2170
  作者：Senning,A.、Rasmussen,J.S.

  DOI：——

  日期：——
• 3H-1,2,4-Dithiazol-3-one compounds as novel potential affordable antitubercular agents
  作者：Jianzhong Yang、Weiyi Pi、Li Xiong、Wei Ang、Tao Yang、Jun He、Yuanyuan Liu、Ying Chang、Weiwei Ye、Zhenling Wang、Youfu Luo、Yuquan Wei

  DOI：10.1016/j.bmcl.2012.12.065

  日期：2013.3

  Small molecules with oxathiazol-2-one moiety were recently reported as potent inhibitors of Mycobacterium bovis var. bacilli Calmette-Guerin (BCG), among which HT1171 was the most potent and selective proteasome inhibitor. Herein we synthesized a series of novel compounds by bioisosteric replacement of the oxathiazol-2-one ring with 3H-1,2,4-dithiazol-3-one, and also fifteen 1,3,4-oxathiazol-2-one molecules in order for potency comparison and structure-activity relationship elucidation since their antibacterial effects on the virulent strains were not evaluated before. All the compounds were assessed for antitubercular activities on the virulent H37Rv strain by a serial dilution method. Among the tested compounds, 3H-1,2,4-dithiazol-3-one compound 4n was found to be the most active with a lowest MIC90 value of 1 mu g/mL. Furthermore, the cytotoxicities of all the compounds against normal human liver cell line L02 were determined by an MTT method. Compound 4n displayed a lower inhibitory ratio than HT1171 at the concentration of 100 mu M, indicating its better safety profile. (C) 2012 Elsevier Ltd. All rights reserved.
• KOVAL, I. V.;OLEJNIK, T. G.;TARASENKO, A. I.;KREMLEV, M. M., ZH. ORGAN. XIMII, 1985, 21, N 12, 2578-2587
  作者：KOVAL, I. V.、OLEJNIK, T. G.、TARASENKO, A. I.、KREMLEV, M. M.

  DOI：——

  日期：——
• PROTEASOME INHIBITORS AND THEIR USE IN TREATING PATHOGEN INFECTION AND CANCER
  申请人：Nathan Carl

  公开号：US20110118274A1

  公开（公告）日：2011-05-19

  The present invention relates to proteasome inhibitors and their use in methods of treating a subject for a pathogen infection or cancer. The methods involve administering to the subject a compound of Formula (I). (I) where: Q is Formula or Formula, where the crossing dashed line illustrates the bond formed joining Q to the rest of the compound of Formula (I). The remainder of substituents of the compound of Formula (I) are defined in the present application.